Common Use

Myrbetriq is an innovative prescription medication containing mirabegron, a first-in-class beta-3 adrenergic agonist specifically developed and approved for the treatment of overactive bladder (OAB) — a chronic urological condition characterized by a distressing combination of urinary urgency, frequent urination (urinary frequency), nocturia (waking at night to urinate), and urge urinary incontinence (involuntary urine leakage associated with a sudden, compelling need to urinate). Unlike traditional anticholinergic medications that have long been the standard treatment for overactive bladder, mirabegron works through an entirely different and innovative pharmacological mechanism: it activates beta-3 adrenergic receptors located in the detrusor muscle of the bladder wall, causing the smooth muscle to relax during the bladder filling phase. This relaxation effectively increases the functional storage capacity of the bladder, reduces the frequency and intensity of involuntary bladder contractions, and allows the bladder to hold more urine comfortably before the urge to void becomes compelling. When you buy Myrbetriq online from our pharmacy, you access a clinically proven bladder control medication that offers meaningful relief from the embarrassing and life-limiting symptoms of OAB without the troublesome anticholinergic side effects — such as severe dry mouth, constipation, blurred vision, and cognitive impairment — that cause many patients to discontinue traditional overactive bladder treatments. As a Myrbetriq generic equivalent, mirabegron delivers the same therapeutic benefits for urinary incontinence and frequent urination management at an accessible price. Clinical trials have demonstrated that mirabegron significantly reduces the number of daily incontinence episodes, decreases urinary frequency, increases the volume voided per micturition, and improves patient-reported quality of life scores — making it a preferred first-line or second-line treatment option for millions of adults living with overactive bladder symptoms worldwide.

Dosage and Direction

Take Myrbetriq orally once daily, with or without food, at approximately the same time each day as directed by your healthcare provider. The recommended starting dose of mirabegron is 25 mg once daily, which may be increased to the standard effective dose of 50 mg once daily after approximately 8 weeks based on your individual clinical response and tolerability. Swallow the extended-release tablet whole with a full glass of water — do not crush, chew, split, or dissolve the tablet, as doing so will disrupt the extended-release mechanism and may cause the entire dose to be released at once, increasing the risk of side effects and reducing the duration of therapeutic effect. Consistent daily dosing is important for achieving and maintaining optimal bladder control, as mirabegron reaches steady-state plasma concentrations after approximately one week of regular use. Your healthcare provider will determine the most appropriate dose based on your symptom severity, blood pressure readings, kidney and liver function, and your response to initial therapy. It may take several weeks of consistent treatment before you experience the full therapeutic benefit of this beta-3 agonist medication — be patient and continue taking Myrbetriq as prescribed even if you do not notice immediate improvement in your overactive bladder symptoms. Do not exceed the maximum recommended dose of 50 mg daily. If you have moderate hepatic impairment (Child-Pugh Class B) or severe renal impairment (eGFR 15 to 29 mL/min/1.73m²), the maximum recommended dose is 25 mg once daily.

Precautions

Before you buy mirabegron or begin Myrbetriq treatment, inform your healthcare provider thoroughly about your complete medical history, paying particular attention to any existing high blood pressure (hypertension), as mirabegron can cause dose-related increases in blood pressure that require regular monitoring — your doctor should check your blood pressure before starting treatment and periodically throughout therapy, especially during the first few months. Report any history of kidney disease or impaired renal function, liver disease or hepatic impairment, urinary retention or bladder outlet obstruction (such as from an enlarged prostate), and any cardiac conditions including uncontrolled hypertension, irregular heart rhythm, or QT prolongation. Patients with severe uncontrolled hypertension (systolic blood pressure equal to or greater than 180 mmHg and/or diastolic blood pressure equal to or greater than 110 mmHg) should not use this medication until their blood pressure has been brought under adequate control. Myrbetriq should be used with caution in patients with bladder outlet obstruction or those taking concurrent antimuscarinic medications for overactive bladder, as the combination may increase the risk of urinary retention — report any difficulty starting urination, weak urine stream, or sensation of incomplete bladder emptying to your doctor immediately. If you are pregnant, planning pregnancy, or breastfeeding, discuss the potential risks and benefits of mirabegron with your healthcare provider, as there is limited data on its use during pregnancy and it is not known whether the drug passes into breast milk. Inform your doctor about all medications you are currently taking, as mirabegron is an inhibitor of the CYP2D6 enzyme and the P-glycoprotein transporter, which can affect the blood levels of several important medications.

Contraindications

Do not use Myrbetriq if you have a known allergy or hypersensitivity to mirabegron or any other inactive ingredient in the tablet formulation. This beta-3 agonist medication is contraindicated in patients with severe uncontrolled high blood pressure (defined as systolic blood pressure equal to or greater than 180 mmHg and/or diastolic blood pressure equal to or greater than 110 mmHg), as mirabegron can further elevate blood pressure and increase the risk of hypertensive crisis, stroke, or other serious cardiovascular events. Myrbetriq should not be used in patients with end-stage renal disease (eGFR below 15 mL/min/1.73m² or patients requiring dialysis) or severe hepatic impairment (Child-Pugh Class C), as the pharmacokinetics of mirabegron are significantly altered in these populations, leading to unpredictable drug accumulation and increased toxicity risk. Myrbetriq generic formulations carry identical contraindications. Patients who have previously experienced angioedema (severe swelling of the face, lips, tongue, or throat) in response to mirabegron must not be re-exposed to this medication under any circumstances. Urinary retention due to bladder outlet obstruction that has not been adequately evaluated or treated is a relative contraindication, as relaxation of the detrusor muscle may exacerbate retention in susceptible individuals.

Possible Side Effect

Common side effects of mirabegron include increased blood pressure (the most pharmacologically predictable effect, typically a mild elevation of 1-3 mmHg that requires monitoring), headache, nasopharyngitis (common cold symptoms), urinary tract infections, constipation, diarrhea, nausea, dizziness, and tachycardia (increased heart rate). These effects are generally mild to moderate in severity and often improve or stabilize with continued treatment. Notably, Myrbetriq is significantly less likely to cause the bothersome anticholinergic side effects — severe dry mouth, constipation, blurred vision, drowsiness, and cognitive impairment — that frequently lead to discontinuation of traditional overactive bladder medications, making it better tolerated for long-term bladder control management. Less common but clinically important side effects include urinary retention (difficulty emptying the bladder completely), which may be more likely in patients with pre-existing bladder outlet obstruction, elevated liver enzymes, joint pain, and back pain. Rare but serious adverse effects include angioedema (severe allergic swelling of the face, lips, tongue, or throat that can obstruct breathing and requires emergency treatment), severe hypertension or hypertensive crisis, atrial fibrillation or other cardiac arrhythmias, and serious hypersensitivity reactions including Stevens-Johnson syndrome. Contact your healthcare provider promptly if you experience significant blood pressure elevation, persistent rapid heartbeat, difficulty urinating, signs of urinary tract infection (burning, frequent small-volume urination, cloudy or bloody urine), or any symptoms of allergic reaction including rash, itching, swelling, or difficulty breathing.

Drug Interaction

Myrbetriq has several clinically important drug interactions that your healthcare provider should be aware of. Mirabegron is a moderate inhibitor of the CYP2D6 enzyme, meaning it can increase the blood levels of medications that are metabolized by this enzyme — including metoprolol (a commonly used beta-blocker, whose exposure may be significantly increased), desipramine, flecainide, propafenone, thioridazine, and certain other antidepressants, antipsychotics, and antiarrhythmic drugs. Dose adjustments of these CYP2D6 substrates may be necessary when used concurrently with mirabegron. Mirabegron also inhibits the P-glycoprotein (P-gp) transporter, potentially increasing the absorption and blood levels of digoxin — if digoxin is co-administered, it should be initiated at the lowest dose and digoxin levels should be monitored closely. The combination of Myrbetriq with other beta-adrenergic agonists or sympathomimetic drugs may enhance adrenergic effects on the cardiovascular system, potentially increasing heart rate and blood pressure. When used together with antimuscarinic agents (such as solifenacin or oxybutynin) for enhanced overactive bladder control, there may be an increased risk of urinary retention — monitor closely for signs of incomplete bladder emptying. Concurrent use with warfarin requires monitoring of INR, as the interaction potential exists. Antihypertensive medications used concurrently should be monitored, as the blood pressure-raising effect of mirabegron may partially counteract their therapeutic benefit. Certain antifungal medications (ketoconazole, itraconazole) and macrolide antibiotics (clarithromycin, erythromycin) that inhibit CYP3A4 can moderately increase mirabegron exposure. Always inform your healthcare provider about all prescription medications, over-the-counter drugs, vitamins, and herbal supplements you are taking before starting this overactive bladder treatment.

Missed Dose

If you miss a dose of Myrbetriq, take it as soon as you remember on the same day. If it is already close to the time for your next scheduled dose, skip the missed dose and continue with your regular once-daily dosing schedule — do not take two tablets at the same time or within a short interval to compensate for the missed dose, as this could increase the risk of blood pressure elevation, tachycardia, and other dose-related side effects. Consistent daily dosing is important for maintaining optimal bladder control and reducing the frequency of urge incontinence and frequent urination episodes. If you regularly forget your medication, consider practical strategies such as setting a daily phone alarm, using a weekly pill organizer, placing the medication next to an item you use every day (such as your morning coffee cup or toothbrush), or using a medication reminder app. If you miss several consecutive doses, resume your regular dosing schedule without doubling up, and contact your healthcare provider if your overactive bladder symptoms return or worsen significantly.

Overdose

In case of Myrbetriq overdose, seek emergency medical attention promptly. Symptoms of mirabegron overdose may include rapid heartbeat (tachycardia), palpitations, elevated blood pressure (hypertension) that may reach dangerous levels, dizziness, headache, and tremor. In clinical studies, single doses of up to 400 mg (8 times the maximum recommended dose) were associated with increased heart rate and elevated systolic blood pressure. Severe overdose may potentially cause hypertensive crisis, dangerous cardiac arrhythmias, or other cardiovascular complications requiring emergency intervention. There is no specific antidote for mirabegron overdose. Treatment is supportive and symptomatic, focusing on cardiovascular monitoring, blood pressure management with appropriate antihypertensive agents, heart rate control, and general supportive care. Hemodialysis is unlikely to be effective for drug removal, as mirabegron is highly protein-bound. Gastric decontamination measures including activated charcoal may be considered if the patient presents within 1 to 2 hours of ingestion. Monitor the patient closely for cardiac arrhythmias and blood pressure changes for an extended period following significant overdose.

Storage

Store Myrbetriq at controlled room temperature between 20°C and 25°C (68°F to 77°F), with brief temporary excursions permitted between 15°C and 30°C (59°F to 86°F). Protect the medication from moisture, excessive heat, and direct light exposure. Keep the tablets in their original container, tightly closed with the child-resistant cap, and with any included desiccant packet left in place to absorb residual moisture. Do not store this bladder control medication in the bathroom, near the kitchen sink, or in any humid environment. Keep Myrbetriq and all medications out of the reach of children and pets. Do not use tablets that are past their expiration date or that show visible signs of deterioration such as discoloration, crumbling, or unusual odor. Dispose of expired or unused mirabegron tablets safely and responsibly according to your pharmacist's recommendations or through local community medication take-back programs.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.